Epsilogen licenses first-in-class IgE ovarian cancer drugUK biotech Epsilogen has licensed rights to a drug for solid tumours developed by Kings College London and Share XEpsilogen licenses first-in-class IgE ovarian cancer drughttps://pharmaphorum.com/news/epsilogen-licenses-first-in-class-ige-ovarian-cancer-drug/
